Market Place
Sourcing Support
AVEO Oncology Presents TiNivo-2 And TIVO-3 Results At ESMO 2024
16 Sep 2024 //
PR NEWSWIRE
AVEO Oncology Announces Late-Breaking TiNivo-2 Oral Presentation at ESMO
03 Sep 2024 //
PR NEWSWIRE
LG Chem, AVEO: LG`s First Anti-Cancer Compound Enters Phase 1
13 Jun 2024 //
PR NEWSWIRE
AVEO Announces Completion of Enrollment in Pivotal Ph3 TiNivo-2 Study of FOTIVDA
27 Jun 2023 //
PR NEWSWIRE
Korean buyer jumps into M&A game with $566M bid for Aveo Oncology
19 Oct 2022 //
ENDPTS
LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash
18 Oct 2022 //
PRESS RELEASE
U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Use of FOTIVDA®
12 Oct 2022 //
GLOBENEWSWIRE
AVEO Oncology Announces Participation at the Cantor Fitzgerald Oncology
21 Sep 2022 //
GLOBENEWSWIRE
AVEO Oncology Announces Participation at Investor Conferences in September
31 Aug 2022 //
GLOBENEWSWIRE
AVEO Oncology Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
AVEO Oncology to Announce Second Quarter 2022 Financial Results
28 Jul 2022 //
GLOBENEWSWIRE
AVEO & Lilly Sign Trial Collaboration and Supply Agreement for ERBITUX
22 Jun 2022 //
GLOBENEWSWIRE
AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO
06 Jun 2022 //
GLOBENEWSWIRE
AVEO Oncology Announces Participation at the H.C. Wainwright Conference
18 May 2022 //
GLOBENEWSWIRE
AVEO Oncology Reports First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
AVEO Oncology to Announce First Quarter 2022 Financial Results
28 Apr 2022 //
GLOBENEWSWIRE
AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results
14 Mar 2022 //
GLOBENEWSWIRE
AVEO Oncology to Announce FY 2021 Financial Results
07 Mar 2022 //
GLOBENEWSWIRE
Actinium and Aveo partner for antibody radio-conjugate for solid tumour
23 Feb 2022 //
PHARMACEUTICAL-TECHNOLOGY
Actinium and AVEO Oncology Collaborate to Develop Actinium-225 ErbB3
22 Feb 2022 //
PRNEWSWIRE
AVEO Oncology to Present Positive PFS Data from Phase 3 TIVO-3 Study of FOTIVDA
14 Feb 2022 //
GLOBENEWSWIRE
AVEO Presents 3 Posters for Tivozanib/Immunotherapy Combinations at 2022 ASCO GI
20 Jan 2022 //
GLOBENEWSWIRE
NiKang, AVEO Oncology Announce a Clinical Trial Collaboration & Supply Agreement
05 Jan 2022 //
BUSINESSWIRE
AVEO Collaborates with Merck KGaA to Evaluate Ficlatuzumab and ERBITUX in HNSCC
04 Jan 2022 //
BIOSPACE
AVEO Reports Q3 2021 Financial Results and Provides Business Update
08 Nov 2021 //
BUSINESSWIRE
FDA Grants FTD to AVEO Oncology`s Ficlatuzumab for r/r HNSCC
20 Sep 2021 //
BUSINESSWIRE
AVEO Oncology Announces Participation at Upcoming Virtual Investor Conferences
30 Aug 2021 //
BUSINESSWIRE
AVEO Oncology Reports Second Quarter 2021 Financial Results
05 Aug 2021 //
BUSINESSWIRE
AVEO Oncology to Announce Second Quarter 2021 Financial Results
29 Jul 2021 //
BUSINESSWIRE
AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA
07 Jul 2021 //
BUSINESSWIRE
AVEO to Host KOL Webinar on Ficlatuzumab in H & N Squamous Cell Carcinoma
07 Jun 2021 //
BUSINESSWIRE
AVEO Oncology Announces Positive Results from Randomized Phase 2 Study
18 May 2021 //
AVEOONCOLOGY
AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up
18 May 2021 //
AVEOONCOLOGY
AVEO Oncology Announces Addition of FOTIVDA® (tivozanib)
29 Mar 2021 //
PRESS RELEASE
AVEO Oncology Announces Addition of FOTIVDA® (tivozanib)
29 Mar 2021 //
BUSINESSWIRE
AVEO Oncology Announces U.S. Commercial Availability of FOTIVDA®
22 Mar 2021 //
BUSINESSWIRE
AVEO Announces Proposed Public Offering of Common Stock
22 Mar 2021 //
BUSINESSWIRE
AVEO Oncology to Regain Ex-North American Rights to AV-203
15 Mar 2021 //
BUSINESSWIRE
AVEO Oncology Announces Collaboration with Bristol Myers Squibb to FOTIVDA®
12 Mar 2021 //
BUSINESSWIRE
AVEO Oncology Announces Collaboration with Bristol Myers to Evaluate FOTIVDA®
12 Mar 2021 //
BUSINESSWIRE
Aveo teams with Bristol Myers after surprise FDA approval; CalciMedica up $21M
12 Mar 2021 //
ENDPTS
Aveo`s tivozanib, after years of setbacks, wins its FDA nod
11 Mar 2021 //
FIERCEPHARMA
AVEO Oncology Announces Drawdown of $20 Million Tranche
11 Mar 2021 //
BUSINESSWIRE
Aveo gets FDA nod for Fotivda in third-line kidney cancer
11 Mar 2021 //
BUSINESSWIRE
AVEO Oncology Announces U.S. FDA Approval of FOTIVDA® (tivozanib)
10 Mar 2021 //
BUSINESSWIRE
FDA approves AVEO’s kidney cancer treatment
10 Mar 2021 //
PHARMAFILE
AVEO Oncology Announces Presentation of Key Subgroup and Quality
11 Feb 2021 //
BUSINESSWIRE
AVEO Oncology Announces Presentation of Key Subgroup and Quality of Life
11 Feb 2021 //
BUSINESSWIRE
AVEO Oncology announces positive results from phase portion of DEDUCTIVE trial
20 Jan 2021 //
PHARMABIZ
AVEO Oncology Announces Commitment for an Incremental $10 Million Loan
20 Jan 2021 //
BUSINESSWIRE
AVEO Oncology Announces Commitment for an Incremental $10 Million Loan i
20 Jan 2021 //
BUSINESSWIRE
AVEO Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib
15 Jan 2021 //
BUSINESSWIRE
AVEO Oncology Announces Results from Ph 1b of DEDUCTIVE Study of Tivozanib
15 Jan 2021 //
PRNEWSWIRE
AVEO Oncology Highlights Recent Progress and 2021 Outlook
07 Jan 2021 //
BUSINESSWIRE
AVEO Oncology Announces Webcast of Presentation at the 39th Annual
04 Jan 2021 //
BUSINESSWIRE
AVEO Oncology Announces Data from Study of Tivozanib in Renal Cell Carcinoma
15 Sep 2020 //
BUSINESSNEWS WIRE
AVEO Oncology Regains Full Global Rights to Ficlatuzumab
08 Sep 2020 //
BUSINESS WIRE
AVEO Oncology Announces Restructuring of Existing Term Loan with Closing
10 Aug 2020 //
BUSINESSWIRE
AVEO Oncology Announces $2.8M Development Milestone Earned from Kyowa Kirin
05 Aug 2020 //
BUSINESSWIRE
AVEO Announces Pricing of $44.6 Million Public Offering of Common Stock
17 Jun 2020 //
BUSINESSWIRE
